NCT02288234

Telavancin Observational Use Registry (TOUR)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,063 (actual)
• Sponsor: Cumberland Pharmaceuticals · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who are receiving clinician directed telavancin therapy.

Detailed description

This is a retrospective medical chart review, multicenter, observational study to examine telavancin efficacy and safety in a real-word setting and to characterize the pattern of use of telavancin in hospital-based inpatients and in outpatient infusion centers. All treatment decisions and clinical assessment will be made at the discretion of the treating physician per usual care and are not mandated by study design or protocol.

Conditions

• Hospital Acquired Bacterial Pneumonia
• Complicated Skin and Skin Structure Infections
• Ventilator Associated Bacterial Pneumonia
• Gram Positive Infection

Interventions

Type	Name	Description
DRUG	Vibativ	This is an observational study for patients who were already prescribed Vibativ.

Timeline

• Start date: 2014-11-01
• Primary completion: 2017-06-01
• Completion: 2017-10-01
• First posted: 2014-11-11
• Last updated: 2019-01-15

Locations

1 site across 1 country: United States